CYCELRION THERAPEUTICS, INC.
245 First Street, 18th Floor
Cambridge, MA 02142
June 21, 2021
By EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
| Re: | Cyclerion Therapeutics, Inc. (the “Company”) |
|
|
Registration Statement on Form S-3 |
|
|
File No. 333-257145
|
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests acceleration of the effective date
of the above referenced Registration Statement to 4:00 p.m., Eastern time, on June 23, 2021, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Hughes Hubbard & Reed LLP, request by telephone that
such Registration Statement be declared effective.
Please contact Gary J. Simon, of Hughes Hubbard & Reed LLP, special counsel to the Company, at (212) 837-6770, as soon as the
Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
|
|
Very truly yours,
|
||
|
|
|
|
|
|
|
CYCLERION THERAPEUTICS, INC. | ||
|
|
|
|
|
|
|
By: | /s/ Anjeza Gjino | |
|
|
|
Name: | Anjeza Gjino |
|
|
|
Title: | Chief Financial Office |
| cc: | Hughes Hubbard & Reed LLP |